A Study of SYH2053 Injection in Participants With Hepatic Impairment Compared to Participants With Normal Hepatic Function
A Phase I Clinical Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of SYH2053 Injection in Participants With Mild Hepatic Impairment (Child-Pugh Class A), Moderate Hepatic Impairment (Child-Pugh Class B), and Normal Hepatic Function.
This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of SYH2053 injection in participants with mild, and moderate hepatic impairment compared to participants with normal hepatic function.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Clinical Trials Information Group NA officer
- 電話番号:86-0311-69085587
- メール:ctr-contact@cspc.cn
研究場所
-
-
Shandong
-
Jinan、Shandong、中国、250014
- 募集
- the First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
-
コンタクト:
- wei zhao Chief pharmacist, Pharmaciae Doctor
- 電話番号:CN 0531-89268212
- メール:zhao4wei2@hotmail.com
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged between 18 and 75 years (inclusive), males or females.
- Body weight ≥ 45.0 kg for females or ≥ 50.0 kg for males, and body mass index (BMI) between 18 and 32 kg/m² (inclusive), where BMI = weight (kg) / height² (m²).
- LDL-C ≥ 70 mg/dL (1.8 mmol/L) at the screening visit.
- Participants must be able to communicate well with the investigator and be willing and able to comply with all protocol requirements throughout the study.
- For participants with hepatic impairment: patients with chronic hepatic impairment or cirrhosis caused by primary liver diseases (e.g., viral hepatitis, alcoholic liver disease, autoimmune hepatitis, etc.), classified as Child-Pugh Class A or B at screening; and judged by the investigator to have stable disease status for at least 1 month based on clinical presentation and other findings.
- For participants with hepatic impairment: stable treatment for hepatic impairment, its complications, and other concomitant diseases for at least 1 month prior to study drug administration, with no anticipated dose adjustments needed during the study.
- For participants with hepatic impairment: except for hepatic insufficiency and its complications, the subject's physical condition is deemed acceptable based on assessments of vital signs, physical examination, laboratory tests, 12-lead electrocardiogram, chest X-ray, ultrasound examination, and routine electroencephalogram.
- For participants with normal hepatic function: subjects are matched to participants in the hepatic insufficiency group by body weight (within ±10 kg), age (within ±10 years), and sex, allowing a sex count difference of up to ±1 between the two groups.
- For participants with normal hepatic function: physical examination, vital signs, laboratory tests, 12-lead electrocardiogram, chest X-ray, and ultrasound examination show results that are either normal or abnormal but without clinical significance.
Exclusion Criteria:
- History of severe allergic reactions, including but not limited to anaphylactic shock and severe generalized urticaria, or documented hypersensitivity to oligonucleotide-based therapeutics.
- Initiation of or unstable use of lipid-lowering agents, or drugs or supplements with lipid-modulating effects as determined by the investigator, within 30 days prior to screening, including but not limited to statins, fibrates, ezetimibe/hyzetimibe, red yeast rice, niacin, omega-3 fatty acids, stanols, or bile acid sequestrants; use of PCSK9 monoclonal antibodies or oral PCSK9 inhibitors within 180 days prior to screening; or use of Leqvio® (inclisiran) or any other RNA-based therapy for lipid-lowering purposes within 2 years prior to screening, including but not limited to siRNA or antisense oligonucleotide therapy.
- Participation in any clinical trial and receipt of investigational drug within 5 half-lives of the study drug or within 90 days prior to screening (whichever is longer), or plan to participate in any other clinical trial during the study period.
- Average daily smoking of more than 5 cigarettes (or equivalent tobacco in e-cigarettes) within 3 months prior to screening, and/or unwillingness to refrain from using any tobacco products during the study period.
- Subjects with habitual alcohol use within 6 months prior to screening, defined as consumption of more than 14 units of alcohol per week (1 unit = 360 mL of beer [5% alcohol], 45 mL of spirits [40% alcohol], or 150 mL of wine [12% alcohol]); and/or those who are unable to refrain from alcohol consumption during the study period; and/or those with a positive breath alcohol test at screening.
- History of drug abuse, and/or a positive urine drug screening test.
- Daily consumption of excessive tea, coffee, and/or caffeinated beverages (8 cups or more per day, 1 cup = 250 mL) within 1 month prior to screening, and/or unwillingness to refrain from consuming tea, coffee, and/or caffeinated foods, grapefruit (pomelo) and/or grapefruit juice, and/or poppy seed-containing products during the study period.
- Blood loss or blood donation exceeding 200 mL within 3 months prior to screening, and/or platelet donation within 2 weeks prior to screening, or planned blood donation during the study period.
- Pregnant or lactating women; female participants of childbearing potential with a serum pregnancy test result exceeding the upper limit of normal at screening; or female participants who had unprotected sexual intercourse within 2 weeks prior to screening.
- Planned pregnancy (including sperm donation or egg donation) from the signing of the informed consent form (ICF) until 6 months after study drug administration, and/or unwillingness to adopt effective non-pharmacological contraceptive methods.
- Any other condition that, in the investigator's opinion, makes the participant unsuitable for participation in this clinical trial.
- For participants with hepatic impairment: active hepatitis B or hepatitis C at screening.
- For participants with hepatic impairment: subjects who meet any of the following criteria at screening and/or baseline (if applicable) are excluded: a) Positive for HIV antibody or syphilis antibody; b) Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², calculated using the CKD-EPI formula; c) Glycated hemoglobin (HbA1c) > 8.5%; d) Systolic blood pressure (SBP) ≥ 160 mmHg or diastolic blood pressure (DBP) ≥ 100 mmHg; e) Platelet count < 20 × 10⁹/L; f) Hemoglobin < 80 g/L.
- For participants with hepatic impairment: drug-induced liver injury; history of liver transplantation; hepatorenal syndrome.
- For participants with hepatic impairment: acute hepatic injury from any cause within 2 months prior to screening.
- For participants with hepatic impairment: severe ascites or pleural effusion requiring paracentesis or drainage.
- For participants with hepatic impairment: diseases affecting bile excretion, such as biliary cirrhosis, biliary obstruction, or cholestatic liver disease.
- For participants with hepatic impairment: severe portal hypertension or prior portosystemic shunt surgery, including transjugular intrahepatic portosystemic shunt (TIPS).
- For participants with hepatic impairment: hepatic failure at screening, or cirrhosis complicated by hepatic encephalopathy, hepatocellular carcinoma, esophageal or gastric variceal bleeding, or other complications deemed unsuitable by the investigator.
- For participants with hepatic impairment: any current or prior (within 24 weeks prior to screening) clinical disease involving the circulatory, endocrine, neuropsychiatric, digestive, respiratory, hematologic, or urinary systems that, in the investigator's assessment, makes the participant unsuitable for participation in the trial.
- For participants with normal hepatic function: use of any medication within 14 days or 5 half-lives (whichever is longer) prior to dosing (with the exception of topical preparations exerting local effects).
- For participants with normal hepatic function: positive for hepatitis B surface antigen, hepatitis C virus antibody, HIV antibody, or syphilis antibody.
- For participants with normal hepatic function: any current or prior (within 24 weeks prior to screening) severe or chronic disease involving the circulatory, endocrine, neuropsychiatric, digestive, respiratory, hematologic, or urinary systems, or any other disease that may interfere with the trial results.
- For participants with normal hepatic function: physical examination and/or laboratory findings at screening suggesting the presence or potential presence of hepatic impairment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:SYH2053 (normal hepatic function)
|
SYH2053 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand. |
|
実験的:SYH2053 (mild hepatic function)
|
SYH2053 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand. |
|
実験的:SYH2053 (moderate hepatic function)
|
SYH2053 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Amount excreted unchanged in urine (Ae) of SYH2053 over 72 hours post-dose
時間枠:Pre-dose and multiple timepoints up to 4 days
|
Pre-dose and multiple timepoints up to 4 days
|
|
Fraction excreted (fe) of SYH2053 over 72 hours post-dose
時間枠:Pre-dose and multiple timepoints up to 4 days
|
Pre-dose and multiple timepoints up to 4 days
|
|
Renal clearance (CLr) of SYH2053
時間枠:Pre-dose and multiple timepoints up to 4 days
|
Pre-dose and multiple timepoints up to 4 days
|
|
Maximum observed plasma concentration (Cmax)
時間枠:Pre-dose and multiple timepoints up to 4 days
|
Pre-dose and multiple timepoints up to 4 days
|
|
Area under the curve of the plasma concentration (AUC) from time 0 to the last measurable time (AUC0-t) and from time 0 extrapolated to infinity (AUC0-inf)
時間枠:Pre-dose and multiple timepoints up to 4 days
|
Pre-dose and multiple timepoints up to 4 days
|
|
Time to reach maximum plasma concentration (Tmax) and terminal half-life (t1/2).
時間枠:Pre-dose and multiple timepoints up to 4 days
|
Pre-dose and multiple timepoints up to 4 days
|
|
Pharmacokinetics: Apparent total clearance (CL/F)
時間枠:Pre-dose and multiple timepoints up to 4 days
|
Pre-dose and multiple timepoints up to 4 days
|
|
Pharmacokinetics: Apparent volume of distribution (Vz/F)
時間枠:Pre-dose and multiple timepoints up to 4 days
|
Pre-dose and multiple timepoints up to 4 days
|
|
The serum Low-density lipoprotein cholesterol (LDL-C) level
時間枠:6 months
|
6 months
|
|
The serum PCSK9 level
時間枠:6 months
|
6 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- SYH2053-008
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。